{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:23:49Z","timestamp":1778534629111,"version":"3.51.4"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Proteasome inhibitors can eliminate malignant, alloreactive, or autoreactive plasma cells. These cells are key players in antibody-mediated autoimmune disorders and thus suitable therapeutic targets for these drugs. However, certain proteasome inhibitors cause toxic peripheral neuropathy in patients. Ixazomib (MLN9708, Ninlaro), an oral proteasome inhibitor, has a more favorable safety profile in multiple myeloma patients. Here we tested its efficacy in preventing and treating experimental autoimmune myasthenia gravis (EAMG). Female Lewis rats were treated with two subcutaneous doses of 0.35 mg\/kg of ixazomib per week, starting either 4 weeks before or at disease onset; both substantially lowered final total IgG and rat acetylcholine receptor (AChR) autoantibody levels. Interestingly, two weekly doses of 0.20 mg\/kg of ixazomib for the last 4 weeks did not reduce autoantibody levels. A single dose of 0.50 mg\/kg was acutely toxic in rats. In cultures of thymic cells from early-onset myasthenia gravis (EOMG) patients, 30 nM ixazomib or higher almost completely eliminated plasma cells and halted their IgG and AChR antibody production. We conclude that proteasome inhibition with ixazomib effectively depletes plasma cells from MG patients <jats:italic>in vitro<\/jats:italic> and in a rat model <jats:italic>in vivo<\/jats:italic>. These results encourage further investigations into therapeutic plasma cell targeting for MG patients.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1521432","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T10:46:15Z","timestamp":1747305975000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of MLN9708 (ixazomib) in experimental autoimmune myasthenia gravis and in anti-AChR producing primary thymic cell cultures from myasthenia gravis patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Marina","family":"Man\u00e9-Damas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisela","family":"Nogales-Gadea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannen","family":"Vincken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten","family":"van Beek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nynke J.","family":"van den Hoogen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elbert A. J.","family":"Joosten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Willcox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Duimel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos G.","family":"Maessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc H.","family":"De Baets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Losen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Martinez-Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115723","article-title":"Maintenance of serum antibody levels","volume":"23","author":"Manz","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066092","article-title":"Duration of humoral immunity to common viral and vaccine antigens","volume":"19","author":"Amanna","year":"2007","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02458","article-title":"Challenges and opportunities for consistent classification of human B cell and plasma cell populations","volume":"10","author":"Sanz","year":"2019","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.1.361","article-title":"Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice","volume":"180","author":"DiLillo","year":"2008","journal-title":"J Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02461.x","article-title":"Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production","volume":"9","author":"Perry","year":"2009","journal-title":"Am J Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1084\/jem.126.1.109","article-title":"Resistance of long-lived lymphocytes and plasma cells in rat lymph nodes to treatment with prednisone, cyclophosphamide, 6-mercaptopurine, and actinomycin D","volume":"126","author":"Miller","year":"1967","journal-title":"J Exp Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1275533","article-title":"Rituximab treatment in myasthenia gravis","volume":"14","author":"Vesperinas-Castro","year":"2023","journal-title":"Front Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903555943","article-title":"Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction","volume":"43","author":"Gomez","year":"2010","journal-title":"Autoimmunity"},{"key":"B10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine BM","year":"2006","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"103104","DOI":"10.1016\/j.autrev.2022.103104","article-title":"Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders","volume":"21","author":"Man\u00e9-Damas","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2010.10.024","article-title":"Reduced thymic expression of ErbB receptors without auto-antibodies against synaptic ErbB in myasthenia gravis","volume":"232","author":"Vrolix","year":"2011","journal-title":"J Neuroimmunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.06.027","article-title":"The myasthenia gravis thymus: a rare source of human autoantibody-secreting plasma cells for testing potential therapeutics","author":"Hill","year":"2008","journal-title":"J Neuroimmunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1254.026","article-title":"Scenarios for autoimmunization of T and B cells in myasthenia gravis","volume":"998","author":"Shiono","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"New Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00005792-194902000-00002","article-title":"The pathology of the thymus in myasthenia gravis; a study of 35 cases","volume":"28","author":"Castleman","year":"1949","journal-title":"Med (Baltimore)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903563491","article-title":"Thymic remodeling associated with hyperplasia in myasthenia gravis","volume":"43","author":"Le Panse","year":"2010","journal-title":"Autoimmunity"},{"key":"B24","first-page":"97","article-title":"Cell types required for anti-acetylcholine receptor antibody synthesis by cultured thymocytes and blood lymphocytes in myasthenia gravis","volume":"58","author":"Willcox","year":"1984","journal-title":"Clin Exp Immunol"},{"key":"B25","article-title":"Greatly increased autoantibody production in myasthenia gravis by thymocyte suspensions prepared with proteolytic enzymes","volume":"54","author":"Willcox","year":"1983","journal-title":"Clin Exp Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/1756285608093888","article-title":"Progress in the treatment of myasthenia gravis","volume":"1","author":"Gold","year":"2008","journal-title":"Ther Adv Neurol Disord"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15238","article-title":"The association between anti-acetylcholine receptor antibody level and clinical improvement in myasthenia gravis","volume":"29","author":"Marcuse","year":"2022","journal-title":"Eur J Neurol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.117.6.2220","article-title":"Subpopulations of chicken B lymphocytes","volume":"117","author":"Lifter","year":"1976","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"B32","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202445099","article-title":"Molecular sequelae of proteasome inhibition in human multiple myeloma cells","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2005.11.019","article-title":"Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome","volume":"14","author":"Groll","year":"2006","journal-title":"Structure"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003536","article-title":"Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis","volume":"88","author":"Scheibe","year":"2017","journal-title":"Neurology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2017.08.011","article-title":"Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis","volume":"312","author":"Sveinsson","year":"2017","journal-title":"J Neuroimmunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06559-y","article-title":"Bortezomib is efficacious in the treatment of severe childhood-onset neuropsychiatric systemic lupus erythematosus with psychosis: a case series and mini-review of B-cell immunomodulation in antibody-mediated diseases","volume":"42","author":"Modica","year":"2023","journal-title":"Clin Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301555","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients","volume":"193","author":"Gomez","year":"2014","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis","volume":"186","author":"Gomez","year":"2011","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0476","article-title":"In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells","volume":"17","author":"Chauhan","year":"2011","journal-title":"Clin Cancer Res: An Off J Am Assoc Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2174\/1568009614666140804154511","article-title":"Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system","volume":"14","author":"Dou","year":"2014","journal-title":"Curr Cancer Drug Targets"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.25.25","article-title":"Bortezomib, lenalidomide and dexamethasone vs. Lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777","volume":"126","author":"Durie","year":"2015","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"New Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.expneurol.2015.03.010","article-title":"Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors\u2013Recommendations for methods and experimental designs","volume":"270","author":"Losen","year":"2015","journal-title":"Exp Neurol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J Neurosci Methods"},{"key":"B48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0304-3959(88)90026-7","article-title":"A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia","volume":"32","author":"Hargreaves","year":"1988","journal-title":"Pain"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat","volume":"204","author":"Cavaletti","year":"2007","journal-title":"Exp Neurol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Effects of dexamethasone on lymphocyte proliferation and cytokine production in rheumatoid arthritis","volume":"29","author":"De","year":"2002","journal-title":"J Rheumatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.11.4149","article-title":"Wide variation in lymphocyte steroid sensitivity among healthy human volunteers","volume":"84","author":"Hearing","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.11.6156","article-title":"Variable corticosteroid sensitivity of thymic cortex and medullary peripheral-type lymphoid tissue in myasthenia gravis patients: structural and functional effects","volume":"73","author":"Willcox","year":"1989","journal-title":"Q J Med"},{"key":"B53","volume-title":"Takeda, Safety, tolerability and pharmacokinetics of multiple rising doses of ixazomib in lupus nephritis (LN)","year":"2019"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2017-000215.88","article-title":"88 Ixazomib, an oral proteasome inhibitor, depletes plasma cells reducing autoantibodies and pdcs in pre-clinical model of systemic lupus erythematosus","volume":"4","author":"Itomi","year":"2017","journal-title":"Lupus Sci Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1113\/tjp.2008.586.issue-13","article-title":"Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin A","volume":"586","author":"Rogozhin","year":"2008","journal-title":"J Physiol"},{"key":"B56","first-page":"99","article-title":"Chapter four - the composition, development, and regeneration of neuromuscular junctions","volume-title":"Current Topics in Developmental Biology","author":"Liu","year":"2018"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1084\/jem.144.3.739","article-title":"Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies","volume":"144","author":"Lindstrom","year":"1976","journal-title":"J Exp Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1970","article-title":"The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours","volume":"85","author":"Porrata","year":"2001","journal-title":"Br J Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"New Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282","article-title":"Targeting protein synthesis, folding, and degradation pathways in cancer","author":"Pasqua","year":"2017","journal-title":"Compr Med Chem III"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-725705","article-title":"How I manage the toxicities of myeloma drugs","volume":"129","author":"Delforge","year":"2017","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.855","article-title":"Neonatal paracetamol treatment reduces long-term nociceptive behaviour after neonatal procedural pain in rats","volume":"20","author":"van den Hoogen","year":"2016","journal-title":"Eur J Pain"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4940853","article-title":"Efficacy of Mln9708 (Ixazomib) in experimental autoimmune myasthenia gravis and in anti-achr producing primary thymic cell cultures from myasthenia gravis patients","author":"Man\u00e9-Damas","year":""}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1521432\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T10:46:17Z","timestamp":1747305977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1521432\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":64,"alternative-id":["10.3389\/fimmu.2025.1521432"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1521432","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"article-number":"1521432"}}